Print Page    Close Window

Presentations

DateTitleDownloads
09/05/18
Protalix Biotherapeutics Corporate Update September 2018
Download DocumentationPDF
06/05/18
"Novel Orally Administered Recombinant Anti-TNF alpha Fusion Protein for the Treatment of Ulcerative Colitis: Phase 2a Clinical Trial Showing Promising Results" -- Presentation by Dr. Yaron Ilan at the Digestive Disease Week® (DDW) 2018 Annual Meeting
Download DocumentationPDF
05/25/18
"Progression of Nephropathy in Fabry Patients Receiving Enzyme Replacement Therapy (ERT); Relation to Anti-Drug Antibody (ADA) Status and Proteinuria" -- Poster Presentation by Dr. David Warnock at the at the 55th ERA-EDTA Congress, May 2018
Download DocumentationPDF
02/08/18
"Pegunigalsidase alfa, a Novel PEGylated ERT for Fabry Disease - Two Years Safety and Efficacy Follow Up" -- Poster Presentation by Dr. Derralynn Hughes at the 14th Annual WORLDSymposium(TM) 2018
Download DocumentationPDF
02/08/18
"Enhanced pharmacokinetics profile of pegunigalsidase alfa (PRX-102) supports once-monthly 2mg/kg dosing for the treatment of Fabry disease" -- Poster Presentation by Dr. David G. Warnock at the 14th Annual WORLDSymposium(TM) 2018
Download DocumentationPDF
02/08/18
"Enhanced pharmacokinetics profile of pegunigalsidase alfa (PRX-102) supports once-monthly 2mg/kg dosing for the treatment of Fabry disease" -- Presentation by Dr. David G. Warnock at the 14th Annual WORLDSymposium(TM) 2018
Download DocumentationPDF
11/24/17
“Enzyme replacement therapies in development – preclinical and clinical data and experience with pegunigalsidase alfa” Presentation by Prof. Raphael Schiffmann at the New Horizons in Fabry Disease Conference
Download DocumentationPDF
11/02/17
" Development of Novel Actin Inhibition Resistant DNase I Enzyme - alidornase alfa - for the Treatment of Cystic Fibrosis" -- Poster Presentation by Einat Brill Almon, Ph.D. at the North American Cystic Fibrosis Conference, November 2017
Download DocumentationPDF
06/12/17
“Phase IIa Clinical Trial Results with alidornase alfa for the Treatment of CF” -- Presentation by Professor Eitan Kerem
Download DocumentationPDF
02/16/17
"One-year follow up of Fabry disease patients treated by IV administration of a plant derived alpha-Gal-A enzyme: safety and efficacy” – Presentation by Dr. Derralynn Hughes
Download DocumentationPDF
02/16/17
“PRX-102 for treating Fabry disease – immunogenicity and PK results from a phase 1-2 study” – Presentation by Prof. David Warnock
Download DocumentationPDF
02/15/17
"Pegunigalsidase alfa for treating Fabry disease -- Clinical Pharmacokinetic and Immunogenicity Phase 1/2 Study Results" – Poster Presentation by Prof. David Warnock
Download DocumentationPDF
02/14/17
“Characterization of a chemically modified plant cell culture expressed human α-galactosidase-A enzyme for treatment of Fabry disease” – Presentation by Dr. Yoseph Shaaltiel
Download DocumentationPDF
02/14/17
"pegunigalsidase alfa, a novel PEGylated a-Galactosidase-A ERT for Fabry disease -- Safety and efficacy of 1-year treatment experience" – Poster Presentation by Dr. Derralynn Hughes
Download DocumentationPDF
09/08/16
A Novel Treatment for Fabry Disease – IV Administration of Plant Derived alpha-gal-a Enzyme Safety and Efficacy, 1 Year Experience - Presentation by Raphael Schiffmann, M.D.
Download DocumentationPDF
03/03/16
PRX-102 α-Galactosidase-A; Novel Enzyme Replacement Therapy for the Treatment of Patients with Fabry Disease
Download DocumentationPDF
06/17/15
AIR DNaseTM: Actin Inhibition Resistant Plant Cell Recombinant Chemically Modified Deoxyribonuclease I (DNase I) for the Treatment of Cystic Fibrosis; Presentation by Yoseph Shaaltiel, Ph.D.
Download DocumentationPDF
02/12/15
Novel Treatment for Fabry Disease; IV Administration of Plant Derived α-galactosiodase-A Enzyme, Phase 1/2 Safety and Efficacy Study; Interim Report;" Presentation by Ozlem Goker-Alpan, M.D.
Download DocumentationPDF
02/13/13
Long-Term Safety and Efficacy Data of Taliglucerase Alfa, a Plant Cell–Expressed Recombinant Glucocerebrosidase, in the Treatment of Naïve Gaucher Disease Patients: 36-Month Results
Download DocumentationPDF
02/13/13
A Multicenter, Double-Blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Patients with Gaucher Disease*
Download DocumentationPDF
02/13/13
Plant Cell–Expressed Recombinant Glucocerebrosidase: Taliglucerase Alfa as Therapy for Gaucher Disease in Adult Patients Previously Treated With Imiglucerase: 24-Month Results
Download DocumentationPDF